Financial Shenanigans

The Forensic Verdict

The reported numbers are not faithful representation of recurring economic reality without adjustment, but the distortion is openly disclosed rather than hidden. FY2024 net income of $4.064B contained $2.916B of pre-tax ($2.143B after-tax) gains from hospital divestitures booked inside GAAP operating income — which inflated the FY2024 operating margin to 27.6% versus a 13.4% underlying rate. Cash flow does not lie: 3-year aggregate CFO/Net Income is 1.03x and FCF/Net Income is 0.68x, working-capital does not flatter cash, and DSO actually improved from 52 days (FY2023) to 44 days (FY2025). The two structural concerns that hold this away from a "Watch" grade are (i) a 20-year compliance rap sheet topped by a $900M False Claims Act settlement and a five-year Corporate Integrity Agreement that expired before the most recent reporting period, and (ii) a June 2025 short report from Fuzzy Panda Research alleging fresh Medicare outlier-payment gaming and upcoding, with estimated potential fines of $675M-$845M. The single data point that would most change the grade is a clean disposition of those allegations, either by an explicit company rebuttal with hospital-level cost-report data or by the next 10-K confirming no government inquiry.

Grade: Elevated. Underlying earnings quality is acceptable, but the company's reporting demands aggressive de-noising and the regulatory tail is real. An institutional investor should underwrite the headline numbers at a discount to GAAP operating income, treat FY2024 EPS as a non-comparable base, and reserve a possibility-weighted reserve for outlier-payment claw-back exposure.

Shenanigans Scorecard

Breeding Ground

The structural setup is not founder-controlled or governance-thin, but it has two real amplifiers: incentive design that rewards adjusted metrics over GAAP, and a 20-year history of False Claims Act settlements concentrated in the same coding/outlier areas the new short report alleges. Compensation governance is otherwise reasonable — Say-on-Pay passed at 93% in 2025, the audit committee is independent, Deloitte has rendered unqualified opinions, and there is no record of late filings or material-weakness restatements.

The compensation structure deserves a careful read. The Adjusted EBITDA definition strips out both "net gains (losses) on sales" and "impairment and restructuring charges and acquisition-related costs," so the FY2024 divestitures did not directly inflate management's bonus payout. However, the bar — Adjusted EBITDA of $3,995M in FY2024, $4,566M in FY2025 — sits on a smaller asset base after the divestitures. Margin expansion is partly mix-shift toward USPI ambulatory centers, which carry higher economic margins but also more noncontrolling-interest leakage. Hot-checking the bonus math is worth doing every cycle.

Earnings Quality

The FY2024 income statement is unusable as a like-for-like base. Underneath the divestiture-gain noise, the underlying earnings track is healthier — but the headline cannot be left unadjusted in any model.

The $2.916B FY2024 gain on sale (booked above the operating-income line under "net gains on sales, consolidation and deconsolidation of facilities") is the single biggest earnings-quality call in the file. The FY2024 EPS of $32.70 is overstated by approximately $21.89 per share by the company's own reconciliation. Adjusted FY2024 EPS is roughly $10.81, against $15.49 in FY2025 — that is the actual growth comparison.

Roughly 41% of FY2025 consolidated net income — $960M — flowed to USPI minority partners. Investors who anchor on consolidated net income overstate Tenet's share of earnings by 1.7x. This is structural to the USPI joint-venture model, not a shenanigan, but it makes Adjusted EPS and Adjusted FCF Less NCI the right anchor metrics rather than consolidated cash flow or net income.

Receivables actually fell 13% in FY2024 because the divested hospitals carried their AR off the balance sheet at sale; the FY2025 comparison normalizes. There is no Sherman-style buildup of working capital that would suggest channel-stuffing or aggressive booking. Combined with the DSO improvement to 44 days, this is a genuine earnings-quality positive.

Cash Flow Quality

Underlying cash conversion looks good once the FY2024 tax distortion is taken out, but the volatility year over year is high enough that single-year FCF is a misleading anchor.

The FY2024 inversion — net income of $4.064B but CFO of only $2.047B — is the largest gap in eight years and is fully explained by the $2.916B non-cash gain plus $1.028B higher cash tax payments. FY2025 reversed: CFO $3.540B against NI of $2.367B as the cash taxes normalized and operating efficiency improved. The 3-year aggregate (FY2023-FY2025) tells the truth: $7.96B CFO against $7.74B NI = 1.03x conversion, and $5.27B FCF = 0.68x conversion. Those are reasonable for a hospital + ambulatory-surgery operator.

Acquisition-adjusted FCF is the most useful single number for an acquisitive consolidator. By that measure, FY2025's $2.22B is genuinely strong, FY2024's $0.55B was depressed by both elevated taxes and acquisition cadence, and FY2021's negative $0.31B is a reminder that the USPI buyout cycle can swallow reported FCF. Nothing here suggests CFO is being mechanically inflated through receivable sales, supplier finance, or accelerated collections; the MD&A explicitly attributes FY2024 weakness to "income tax payments that were $1.028 billion higher" and FY2025 strength to "the timing of other working capital items." Both are credible mechanical explanations.

Metric Hygiene

Tenet runs three non-GAAP measures: Adjusted EBITDA, Adjusted EPS, and Adjusted Free Cash Flow (with the variant "Free Cash Flow less NCI"). The reconciliations are clean, included in proxy and 10-K, and have not changed definitions in the last three years. The hygiene risk is not redefinition — it is the gap between non-GAAP and GAAP and the fact that Adjusted EBITDA grew through years of GAAP volatility.

Goodwill rose by $890M from FY2023 to FY2025 even as Tenet divested 14 hospitals. The build is concentrated in USPI: at year-end 2024, $7,994M of $10,691M goodwill (75%) sits in the Ambulatory Care segment versus $2,697M in Hospital Operations. Tenet purchased controlling interests in 54 ASCs and one surgical hospital during FY2024 and another 27+1 in FY2025. Each purchase creates goodwill at acquisition and adds noncontrolling interest on the balance sheet. The qualitative goodwill impairment test passed at October 2024; that test will be the most important single forensic disclosure if USPI growth slows or rates compress.

What to Underwrite Next

The five items that should drive the next quarterly read are concrete and named.

First, monitor the 10-K language around the Fuzzy Panda allegations. A material government inquiry into outlier payments would be required disclosure under Item 3 (Legal Proceedings) and as a subsequent event. The absence of any specific reference in the FY2025 10-K — combined with confirmation that Item 9A internal controls remain effective — would be the single biggest signal that the short thesis is not landing.

Second, track the Adjusted FCF Less NCI figure quarter by quarter and reconcile it to consolidated CFO. The compensation committee uses this measure for both AIP and LTI. The risk is not redefinition; it is whether the noncontrolling-interest distribution number on the cash flow statement equals or exceeds the noncontrolling-interest income on the income statement. If NI to NCI ($960M FY2025) keeps running ahead of cash distributions to NCI for multiple years, joint-venture working capital is silently financing the parent — exactly the kind of disclosure gap to monitor.

Third, watch USPI same-facility revenue and case-volume disclosures. ASC same-facility revenue grew 6.8% in Q1 2025 with a 12% bump in joint replacements; FY2025 case volume was -2.1%. Mix-shift toward higher-acuity (and higher-margin) cases is the official explanation, but if management starts excluding categories from the same-facility cut, that is a metric-hygiene downgrade signal.

Fourth, check whether goodwill keeps building faster than acquisition cash outflows. FY2024 saw $571M of acquisition cash but goodwill rose $384M; FY2025 saw $308M of acquisition cash and goodwill rose $507M. The reconciliation is opaque without the M&A footnote — purchase-price allocation choices, contingent consideration, and step-up of previously held equity interests can all create goodwill without matching cash. A widening cash-to-goodwill gap is a yellow flag for an acquisitive compounder.

Fifth, monitor effective tax rate. FY2025 dropped to 15.5% versus FY2024's 22.6% and a historical 20-25%; the 10-K cites "utilization of interest expense carryforwards due to gains from sales of facilities" as a 2024 item. A repeat low-teens effective rate without comparable gains is a sustainability question for FCF projections.

The signal that would downgrade this work to "Watch" (sub-30): an explicit, detailed company response to the Fuzzy Panda allegations with hospital-level cost-report data, plus a clean FY2025 10-K with no new legal disclosure and continued double-digit organic Adjusted EBITDA growth. The signal that would upgrade this to "High" (60+): any of (i) a Wells notice, formal SEC inquiry, or DOJ subpoena referencing outlier payments or DRG coding; (ii) a material weakness in internal controls; (iii) an unexpected goodwill impairment in either segment; (iv) a redefinition of Adjusted EBITDA or Adjusted FCF Less NCI to expand the addback list.

Bottom line for position sizing. This forensic profile is not a thesis breaker, but it is a position-sizing limiter and a valuation haircut. Underwrite Tenet on Adjusted EBITDA and Adjusted FCF Less NCI rather than GAAP earnings, treat FY2024 as a non-recurring base, and reserve roughly 3-5% of market cap for a possibility-weighted government-claims tail. The compliance history and the live short-seller report mean a long position should carry a wider margin of safety than the underlying cash-conversion picture would otherwise suggest.